Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Galmed Reports Results From The Open-label Part Of The ARMOR Study

Galmed Reports Results From The Open-label Part Of The ARMOR Study

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in

byBenzinga Newsdesk

January 4, 2023

1 minute read

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading
Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan
Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST
Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24
Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is actively looking for partnering opportunities to continue Aramchol’s clinical development.

Lumentum Stock Is Losing Ground After Hours: Here’s Why

By Adam Eckert

April 5, 5:37 PM

Lumentum Holdings Inc (NASDAQ::LITE) shares are falling in extended trading Wednesday after the company reported preliminary fiscal third-quarter results.

LITE